Quebec, Canada (PRWEB) April 12, 2010
Ubiquinone-10 (CoQ10) plays an essential role in the electron transport system, and has been extensively used in food and Pharmaceutical industries. Ubiquinone-10 (Coenzyme Q10), a Vitamin-like lipophilic component of the membrane-bound electron transport system, has a highly functional trans-hydrophobic chain. It has been successfully used therapeutically for cardiovascular diseases and supportive therapy in statin treatment and in mitochondrial respiratory-chain diseases. The antioxidant activity or improved immune function of CoQ10 explains potential anti-cancer effects.
Noreshtech CoQ10 technology will open up new innovation markets and create new innovation products opportunities for manufacturers in the food supplement functional food industry. The Canadian-based Noreshtech Inc has been doing research and has carried out a feasibility study to proceed with a semi-industrial scale test by 2010.
Noreshtech CEO Ms Sheron Harrison says the firm has done a feasibility study and will produce the product in an inside fermentation plant based in Canada. Ms Harrison says the CoQ10 is an interesting investment opportunity for the Company as the ingredient is in demand. She points out that Coenzyme Q10 is labour intenstive and difficult to manufacture and requires bio-chemical engineering expertise. The Company will be marketing their new CoQ10 to Food, Nutraceutical, Pharmaceutical and Cosmeceutical manufacturers. Ms Harrison said that given the fact that opportunity was there, they have made a swift move to produce it for the first time in Canada.
Contact: Ms Sheron Harrison